CVS Health (CVS) – Research Analysts’ Recent Ratings Changes

Posted by on Jun 18th, 2026

A number of research firms have changed their ratings and price targets for CVS Health (NYSE: CVS):

  • 6/13/2026 – CVS Health was downgraded by Wall Street Zen from “buy” to “hold”.
  • 6/11/2026 – CVS Health had its “overweight” rating reaffirmed by Cantor Fitzgerald.
  • 6/8/2026 – CVS Health had its price target raised by Mizuho from $110.00 to $115.00. They now have an “outperform” rating on the stock.
  • 6/8/2026 – CVS Health had its price target raised by UBS Group AG from $100.00 to $115.00. They now have a “buy” rating on the stock.
  • 6/4/2026 – CVS Health had its price target raised by Morgan Stanley from $106.00 to $111.00. They now have an “overweight” rating on the stock.
  • 6/1/2026 – CVS Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $113.00 price target on the stock.
  • 6/1/2026 – CVS Health had its price target raised by Truist Financial Corporation from $102.00 to $108.00. They now have a “buy” rating on the stock.
  • 5/26/2026 – CVS Health had its price target raised by Barclays PLC from $101.00 to $106.00. They now have an “overweight” rating on the stock.
  • 5/20/2026 – CVS Health had its price target raised by Mizuho from $102.00 to $110.00. They now have an “outperform” rating on the stock.
  • 5/14/2026 – CVS Health had its price target raised by Argus from $90.00 to $104.00. They now have a “buy” rating on the stock.
  • 5/14/2026 – CVS Health had its price target raised by Morgan Stanley from $93.00 to $106.00. They now have an “overweight” rating on the stock.
  • 5/12/2026 – CVS Health had its price target raised by JPMorgan Chase & Co. from $101.00 to $111.00. They now have an “overweight” rating on the stock.
  • 5/12/2026 – CVS Health had its price target raised by Sanford C. Bernstein from $94.00 to $106.00. They now have an “outperform” rating on the stock.
  • 5/11/2026 – CVS Health had its price target raised by TD Cowen from $105.00 to $110.00. They now have a “buy” rating on the stock.
  • 5/11/2026 – CVS Health had its price target raised by TD Cowen from $105.00 to $110.00. They now have a “buy” rating on the stock.
  • 5/9/2026 – CVS Health was upgraded by Wall Street Zen from “hold” to “buy”.
  • 5/8/2026 – CVS Health had its “hold (c)” rating reaffirmed by Weiss Ratings.
  • 5/8/2026 – CVS Health had its price target raised by Wells Fargo & Company from $102.00 to $103.00. They now have an “overweight” rating on the stock.
  • 5/7/2026 – CVS Health had its price target raised by Royal Bank Of Canada from $93.00 to $107.00. They now have an “outperform” rating on the stock.
  • 5/7/2026 – CVS Health had its price target raised by Barclays PLC from $93.00 to $101.00. They now have an “overweight” rating on the stock.
  • 5/7/2026 – CVS Health had its price target raised by UBS Group AG from $97.00 to $100.00. They now have a “buy” rating on the stock.
  • 5/7/2026 – CVS Health had its price target raised by Truist Financial Corporation from $98.00 to $102.00. They now have a “buy” rating on the stock.
  • 5/7/2026 – CVS Health had its price target raised by DA Davidson from $80.00 to $100.00. They now have a “buy” rating on the stock.
  • 5/7/2026 – CVS Health had its price target raised by Deutsche Bank Aktiengesellschaft from $88.00 to $92.00. They now have a “buy” rating on the stock.
  • 5/5/2026 – CVS Health had its price target raised by HSBC Holdings plc from $83.00 to $85.00. They now have a “hold” rating on the stock.

Insider Buying and Selling at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. The trade was a 24.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last quarter. Company insiders own 0.85% of the company’s stock.

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Read More

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.